STAT1 activation in squamous cell cancer of the oral cavity: A potential predictive marker of response to adjuvant chemotherapy

Cancer

Volumn 110, Issue 2, 2007, Pages 326-333

  Laimer, Klaus ^a   Spizzo, Gilbert ^a,b   Obrist, Peter ^c   Gastl, Guenther ^a,b   Brunhuber, Thomas ^c   Schäfer, Georg ^c   Norer, Burghard ^a   Rasse, Michael ^a   Haffner, Michael C ^a   Doppler, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Chemotherapy; Oral squamous cell carcinoma; Predictive marker; STAT1; Tissue microarray

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; MITOMYCIN; PARAFFIN; STAT1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL NUCLEUS; CELLULAR DISTRIBUTION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TRANSCRIPTION INITIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOUTH NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; SUBCELLULAR FRACTIONS; TISSUE ARRAY ANALYSIS;

EID: 34547217598     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22813     Document Type: Article

References (45)

1. Ambrosch P. [Epidemiology of oropharyngeal carcinoma]. HNO. 1996;44:2-3.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Koppikar P, deVilliers EM, Mulherkar R. Identification of human papillomaviruses in tumors of the oral cavity in an Indian community. Int J Cancer. 2005;113:946-950.
4. Llewellyn CD, Linklater K, Bell J, Johnson NW, Warnakulasuriya S. An analysis of risk factors for oral cancer in young people: a case-control study. Oral Oncol. 2004;40:304-313.
5. Gandolfo S, Richiardi L, Carrozzo M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol. 2004;40:77-83.
6. Homann N, Tillonen J, Rintamaki H, Salaspuro M, Lindqvist C, Meurman JH. Poor dental status increases acetaldehyde production from ethanol in saliva: a possible link to increased oral cancer risk among heavy drinkers. Oral Oncol. 2001;37:153-158.
7. Moreno-Lopez LA, Esparza-Gomez GC, Gonzalez-Navarro A, Cerero-Lapiedra R, Gonzalez-Hernandez MJ, Dominguez-Rojas V. Risk of oral cancer associated with tobacco smoking, alcohol consumption and oral hygiene: a case-control study in Madrid, Spain. Oral Oncol. 2000;36:170-174.
8. Sasaki T, Moles DR, Imai Y, Speight PM. Clinico-pathological features of squamous cell carcinoma of the oral cavity in patients <40 years of age. J Oral Pathol Med. 2005;34: 129-133.
9. Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer. 1995;75:1343-1353.
10. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345:1890-1900.
11. Howaldt HP, Vorast H, Blecher JC, Reicherts M, Kainz M. [Results of the DOSAK tumor register]. Mund Kiefer Gesichtschir. 2000;4(suppl 1):S216-S25.
12. Malone JP, Stephens JA, Grecula JC, Rhoades CA, Ghaheri BA, Schuller DE. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer. Head Neck. 2004;26:561-572.
13. Sciubba JJ. Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol. 2001;2:239-251.
14. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
15. Laramore GE, Scott CB, al Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23:705-713.
16. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996;36:999-1004.
17. al Sarraf M, Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys. 1997;37:777-782.
18. Nisi KW, Foote RL, Bonner JA, McCaffrey TV. Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: improved local-regional disease control compared with surgery alone. Int J Radiat Oncol Biol Phys. 1998;41: 371-377.
19. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955.
20. Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109:1139-1142.
21. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 2000;19:2489-2495.
22. Xi S, Dyer KF, Kimak M, Zhang Q, et al. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst. 2006;98:181-189.
23. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med. 2002;2:381-392.
24. Porta C, Hadj-Slimane R, Nejmeddine M, et al. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene. 2005;24:605-615.
25. Choi EA, Lei H, Maron DJ, et al. Statl-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res. 2003;63:5299-5307.
26. Mullan PB, Hosey AM, Buckley NE, et al. The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of B. Oncogene. 2005;24:5492-5501.
27. Battle TE, Wierda WG, Rassenti LZ, et al. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003;9:2166-2172.
28. Laimer K, Spizzo G, Gastl G, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. Oral Oncol. 2007;43:193-198.
29. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA. 2000; 97:4227-4232.
30. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 2005;86:347-363.
31. Weber A, Hengge UR, Bardenheuer W, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 2005;24:6699-6708.
32. Masuda M, Toh S, Koike K, et al. The roles of INK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res. 2002;93:329-339.
33. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene. 2005;24: 970-979.
34. Nikitakis NG, Siavash H, Sauk JJ. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr Cancer Drug Targets. 2004;4:637-651.
35. Arany I, Chen SH, Megyesi JK, et al. Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett. 2003;199:83-89.
36. Kondo M, Nagano H, Wada H, et al. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res. 2005;11:1277-1286.
37. Thomas M, Finnegan CE, Rogers KM, et al. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res. 2004;64:8357-8364.
38. McDermott U, Longley DB, Galligan L, Allen W, Wilson T, Johnston PG. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 2005;65:8951-8960.
39. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 2003;22:9063-9074.
40. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer. 2004;4:216-225.
41. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316-323.
42. Townsend PA, Cragg MS, Davidson SM, et al. STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci. 2005;118:1629-1639.
43. Liu K, Caldwell SA, Abrams SI. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res. 2005;65: 4376-4388.
44. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer. 2005;5:397-405.
45. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998;95:7556-7561.